Physician profile
Lance Dulane Jackson
NPI 1356926299
$5,051.74
in general payments reported to CMS, 2019-2025
43 companies · $1,308 in 2025
The $1,308 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $448 · 2022: $841 · 2023: $1,337 · 2024: $1,118 · 2025: $1,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,762.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,282.21 | 2021-2025 | |
| Novo Nordisk INC | $528.31 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Gilead Sciences, INC. | $405.51 | 2023-2025 | Yeztugo |
| Bayer Healthcare Pharmaceuticals INC. | $287.79 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $248.17 | 2022 | |
| Lilly USA, LLC | $240.28 | 2021-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $214.96 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $175.02 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $174.13 | 2021 | |
| Amgen INC. | $171.88 | 2021-2025 | Evenity, Prolia |
| Viiv Healthcare Company | $114.76 | 2024-2025 | Dovato, Apretude |
| Astrazeneca Pharmaceuticals LP | $114.02 | 2023-2025 | |
| Astellas Pharma US INC | $79.35 | 2023-2025 | Veozah, Myrbetriq |
| Almatica Pharma LLC | $74.24 | 2021-2022 | |
| Allergan, INC. | $60.23 | 2021-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $60.07 | 2023 | Rexulti |
| Collegium Pharmaceutical, INC. | $59.75 | 2022 | |
| Grt US Holding, INC. | $57.09 | 2021-2022 | |
| Exact Sciences Corporation | $52.61 | 2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $52.40 | 2025 | |
| Glaxosmithkline, LLC. | $52.09 | 2023 | Shingrix, Trelegy Ellipta, Bexsero |
| Otsuka America Pharmaceutical, INC. | $48.35 | 2025 | Rexulti |
| Currax Pharmaceuticals LLC | $45.24 | 2023-2024 | Contrave, Nexlizet, Nexletol |
| Abiomed | $40.06 | 2025 | |
| Indivior INC. | $38.11 | 2022 | |
| Corium, LLC | $37.15 | 2023 | Azstarys |
| Sanofi Pasteur INC. | $32.37 | 2023 | |
| Bioventus LLC | $25.50 | 2021 | |
| Medtronic, INC. | $24.00 | 2023 | Inpen Smart Insulin Delivery System |
| Axsome Therapeutics, INC. | $22.92 | 2025 | Symbravo |
| Janssen Pharmaceuticals, INC | $22.14 | 2024 | Spravato |
| Sumitomo Pharma America, INC. | $21.28 | 2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $21.04 | 2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.59 | 2024 | Caplyta |
| Exeltis, USA INC. | $20.48 | 2024 | Slynd |
| Ibsa Pharma INC. | $20.14 | 2023 | Tirosint, Licart |
| Electromed, INC. | $18.51 | 2025 | Smartvest |
| Hologic Sales and Service, LLC | $17.75 | 2024 | Aptima, Thinprep 2000 Processor |
| Novartis Pharmaceuticals Corporation | $16.98 | 2025 | |
| Dexcom, INC. | $16.66 | 2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $13.74 | 2023 | Unithroid |
| Scilex Pharmaceuticals INC. | $12.78 | 2022 | |
| Redhill Biopharma INC. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.